Efficacy and safety of cafelkibart (LM-108), an anti-CCR8 monoclonal antibody, in combination with anti-PD-1 therapy in patients with pancreatic cancer: Results from phase 1/2 studies. Long-term ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results